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Abstract
Background: Chlamydia trachomatis was previously shown to express a lipoprotein, the macrophage infectivity
potentiator (Mip), exposed at the bacterial surface, and able to stimulate human primary monocytes/macrophages
through Toll Like Receptor (TLR)2/TLR1/TLR6, and CD14. In PMA-differentiated THP-1 cells the proinflammatory
activity of Mip was significantly higher in the absence than in the presence of serum. The present study aims to
investigate the ability of different serum factors to attenuate Mip proinflammatory activity in PMA-differentiated
THP-1 cells and in primary human differentiated macrophages. The study was also extend to another lipoprotein,
the Borrelia burgdorferi outer surface protein (Osp)A. The proinflammatory activity was studied through Tumor
Necrosis Factor alpha (TNF-a) and Interleukin (IL)-8 release. Finally, TLR1/2 human embryonic kidney-293 (HEK-293)
transfected cells were used to test the ability of the serum factors to inhibit Mip and OspA proinflammatory
activity.
Results: In the absence of any serum and in the presence of 10% delipidated FBS, production of Mip-induced
TNF-a and IL-8 in PMA-differentiated THP-1 cells were similar whereas they were significantly decreased in the
presence of 10% FBS suggesting an inhibiting role of lipids present in FBS. In the presence of 10% human serum,
the concentrations of TNF-a and IL-8 were 2 to 5 times lower than in the presence of 10% FBS suggesting the
presence of more potent inhibitor(s) in human serum than in FBS. Similar results were obtained in primary human
differentiated macrophages. Different lipid components of human serum were then tested (total lipoproteins, HDL,
LDL, VLDL, triglyceride emulsion, apolipoprotein (apo)A-I, B, E2, and E3). The most efficient inhibitors were LDL,
VLDL, and apoB that reduced the mean concentration of TNF-a release in Mip-induced macrophages to 24, 20,
and 2%, respectively (p < 0.0001). These lipid components were also able to prevent TLR1/2 induced activation by
Mip, in HEK-293 transfected cells. Similar results were obtained with OspA.
Conclusions: These results demonstrated the ability of serum lipids to attenuate proinflammatory activity of
bacterial lipoproteins and suggested that serum lipoproteins interact with acyl chains of the lipid part of bacterial
lipoproteins to render it biologically inactive.
Background
Among the bacterial components that trigger macro-
phage activation, the most widely studied is lipopolysac-
charide (LPS) but bacterial lipoproteins have also been
implicated in inflammatory processes [1-3]. Bacterial
lipoproteins are characterized by a unique amino-term-
inal lipo-amino acid, N-acyl-S-diacylglyceryl cysteine [4],
and this lipid element and its peptide moieties are
known to be critical for cell activation through TLR2
[5]. In C. trachomatis,o n es u c hl i p o p r o t e i n ,t h em a c r o -
phage infectivity potentiator (Mip), has been shown to
be present at the bacterial surface [6] and to stimulate
the proinflammatory cytokine response to C. trachoma-
tis in human macrophages through toll like receptor
(TLR)2/TLR1/TLR6 and CD14. The lipid part of Mip
has also been shown to be responsible for its proinflam-
matory activity [2]. However, when stimulation of PMA-
differentiated THP-1 cells was performed in the
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was significantly decreased [2]. Whereas physiological
levels of serum lipoproteins: HDL, LDL, and VLDL have
been found to inactivate LPS [7,8] and bacterial lipotei-
choic acid [9], no study has been reported so far about
the potential of serum lipoproteins to neutralize bacter-
ial lipoproteins. Their ability to neutralize Mip proin-
flammatory activity was therefore investigated. The
study was also extended to another lipoprotein, the Bor-
relia burgdorferi outer surface protein (Osp)A. The
results of the studies included herein showed that total
lipoproteins, HDL, LDL, VLDL, as well as different apo-
lipoproteins and triglycerides prevented proinflamma-
tory activity of Mip and OspA through TLR1/2.
Results
Human serum prevented proinflammatory activity of Mip
in PMA-differentiated THP-1 cells
In a previous report, we showed that TNF-a production
induced by recombinant Mip lipoprotein in PMA-differ-
entiated THP-1 cells was significantly lower in the pre-
s e n c et h a ni nt h ea b s e n c eo f1 0 %F B S[ 2 ] .T oe x t e n d
this observation to another inflammatory cytokine (IL-8)
and to test the effect of other sera, Mip-induced TNF-a
and IL-8 productions were examined in the presence of
10% delipidated FBS or human serum. To normalize dif-
ferent experiments for day to day variations in the
amounts of cytokine produced, data are reported as per-
cent of the cytokine concentration found in the absence
of serum with 100% corresponding to a median TNF-a
concentration of 0.97 ng/ml (interquartile range (IQR)
0.66 - 1.7) and to a median IL-8 concentration of 1.5
ng/ml (IQR 0.56 - 3.2). Whereas in the presence of 10%
FBS the concentrations of TNF-a and IL-8 were signifi-
cantly lower than in the absence of serum (28 ± 32%
and 42 ± 24%, respectively, p < 0.0001), no significant
difference was observed in the presence of delipidated
FBS, suggesting an inhibiting role of lipids present in
FBS. In the presence of 10% human serum, the concen-
trations of TNF-a and IL-8 were also significantly lower
than in the absence of serum (6 ± 9% and 17 ± 28%,
respectively, p < 0.0001) and the mean percentages were
2 to 5 times lower than in the presence of 10% FBS sug-
gesting the presence of more potent inhibitor(s) in the
human serum than in the FBS (Figure 1). The fact that
the LDL level is 5-6 times lower in FBS than in human
serum [10] and that FBS does not contain VLDL [10,11]
in contrast to human serum might explain these results.
Human serum prevented proinflammatory activity of Mip
in primary human differentiated macrophages
To extend our observations to more physiological cells,
the effect of 10% human serum was examined in
primary human differentiated macrophages. The
concentrations of TNF-a and IL-8 were determined in
the cell supernatants after 4 h activation with 1 μg/ml
of recombinant Mip in the presence or absence of 10%
human serum. To normalize different experiments for
day to day variations in the amounts of cytokines pro-
duced, data are reported as percent with 100% corre-
sponding to a median TNF-a concentration of 0.4 ng/
ml (IQR 0.2 - 0.9) and a median IL-8 concentration of
5.8 ng/ml (IQR 5.0 - 7.0). The presence of 10% human
serum markedly decreased production of TNF-a (to 9%
±9 . 5 % ,p < 0.0001) and IL-8 (to 13% ± 25%, p < 0.001)
(Figure 2). These results are similar to those obtained
with PMA-differentiated THP-1 cells.
Total lipoproteins, HDL, LDL, VLDL, and triglyceride
emulsion prevented proinflammatory activity of Mip in
primary human differentiated macrophages
To further examine what serum components can inter-
fere with the proinflammatory activity of Mip, the con-
centrations of TNF-a were determined in the
supernatants of differentiated macrophages after activa-
tion with 1 μg/ml of recombinant Mip in the absence of
serum and in the presence of 200 μg/ml total lipopro-
teins, HDL, LDL, or VLDL. In addition, to determine
whether circulating triglycerides or the triglyceride com-
ponent of VLDL might also interfere with Mip-induced
TNF-a release, the effect of a 0.1% commercial lipid
emulsion composed of long- and medium-chain trigly-
cerides designed for parenteral nutrition (Lipofundin)
was examined. The same concentration was tested for
the different lipoproteins in order to compare their
potential effect. This concentration (200 μg/ml) was
either lower than the concentration in normal serum
(1400 μg/ml HDL protein, 564 μg/ml LDL protein) or
of the same order of magnitude (250 μg/ml VLDL pro-
tein) [12,13]. Likewise, the triglyceride concentration
(0.1%) was of the same order of magnitude as the con-
centration in normal serum (300 - 1400 μg/ml). The
presence of total lipoproteins, HDL, LDL, VLDL, or
0.1% triglyceride emulsion inhibited significantly the
release of TNF-a (to 48 ± 41%, p < 0.05, 53 ± 27%, p <
0.005, 24 ± 20%, p < 0.0001, 20 ± 11%, p < 0.0001, and
44 ± 34%, p < 0.05, respectively, of the TNF-a concen-
tration present in the absence of serum) (Figure 3A)
whereas serum components were devoid of any stimula-
tory effect on TNF-a production in the absence of Mip
(data not shown). The inhibitory effect of HDL, LDL,
VLDL, and triglyceride emulsions were dose-dependent
(Figures 3B, C, D and 3E). These results confirmed the
ability of serum lipids to inhibit Mip-induced TNF-a
release and particularly the high potency of LDL and
VLDL, explaining probably why FBS which contains no
or low concentrations of LDL and VLDL [10,11] is less
inhibitory than human serum. In addition they showed
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nent of VLDL have also the ability to interfer with Mip-
induced TNF-a release.
Human apolipoprotein (apo)A-I, apoB, apoE2, apoE3, and
LPS binding protein (LBP) prevented proinflammatory
activity of Mip in primary human differentiated
macrophages
To further examine the ability of HDL, LDL, and VLDL
to inhibit Mip-induced TNF-a production in primary
human differentiated macrophages, the effect of purified
apoA-I, the major protein component of HDL, and of
purified apoB, apoE2, and apoE3, structural components
of LDL and VLDL, was examined. To compare their
potential effect, the different apolipoproteins were tested
a tt h es a m ec o n c e n t r a t i o n( 1 0μg/ml protein) that was
either lower than the concentration in normal serum
(1400 μg/ml apoA-I, 810 μg/ml apoB) or of the same
order of magnitude (47 μg/ml apoE) [12]. As solubiliza-
tion of apoB necessitates the presence of deoxycholate,
cell cultures were also tested in the presence of the
same concentration of this detergent. The presence of
10 μg/ml of apoA-I, apoB, apoE2, or apoE3 significantly
inhibited Mip induction of TNF-a release to 70 ± 7%,
2.3 ± 0.8%, 26 ± 27%, and 25 ± 15%, respectively (p <
0.05 to < 0.0001), whereas no effect of deoxycholate was
observed on Mip-induced TNF-a production. The most
potent inhibitor was apoB since practically no TNF-a or
IL-8 were detected in the presence of a 10 μg/ml con-
centration (Figure 4A, 4B, and 4C). The TNF-a inhibi-
tion was dose-dependent (Figure 4B). These results
agree with the high inhibitory effect observed in the pre-
sence of LDL and VLDL (Figure 3A).
The possible inhibition by exogenous human LBP was
also examined because LBP is known to circulate in
association with HDL, LDL, VLDL, or chylomicrons
Figure 1 Effect of 10% FBS, delipidated FBS, and human serum on the ability of Mip to induce TNF-a and IL-8 production by PMA-
differentiated THP-1 cells. Cells (2.5 × 10
5 cells/1 ml per well) were cultured with 10 nM PMA for 48 h and then stimulated by recombinant
Mip (1 μg/ml) in the presence or absence of 10% heat-inactivated serum. After 4 h stimulation, supernatants were collected and their content in
TNF-a and IL-8 were analyzed by ELISA. Each value represents the mean ± SD of triplicates from four experiments. ***: p < 0.0001 determined
by comparison with medium alone using Student’s t test.
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approximately corresponds to the amount of LBP pre-
sent in 5% normal human serum [17]. The presence of
1 μg/ml LBP slightly inhibited the Mip induction of
TNF-a release (66% ± 32%) whereas LBP alone did not
affect TNF-a production (Figure 4A).
Overall, these results supported the hypothesis that
both protein and lipid serum components interact with
Mip lipoprotein and prevent its proinflammatory
activity.
Human serum prevented proinflammatory activity of
OspA, E. coli LPS, Pam2CSK4, and Pam3CSK4 in
PMA-differentiated THP-1 cells
To investigate whether the inhibitory effect of human
serum on Mip-induced TNF-a and IL-8 release was a
more general phenomenon, the production of both cyto-
kines was determined in the presence of either 10% FBS
or 10% human serum upon stimulation with another
bacterial lipoprotein (1 μg/ml OspA), two synthetic lipo-
peptides (0.01 μg/ml Pam2CSK4 and Pam3CSK4), or
Figure 2 Effect of 10% human serum on the ability of Mip to induce TNF-a and IL-8 production by primary human differentiated
macrophages. Human monocytes/macrophages (5 × 10
5 cells/0.5 ml per well) were differentiated in a 6-day culture in the presence of 2 ng/ml
M-CSF and then stimulated by recombinant Mip (1 μg/ml) in the presence or absence of 10% heat-inactivated human serum. After 4 h
stimulation, supernatants were collected and their content in TNF-a and IL-8 were analyzed by ELISA. Each value represents the mean ± SD of
triplicates from two experiments. The results are expressed as percent of TNF-a or IL-8 release in the absence of serum. ***: p < 0.0001; **: p <
0.005 determined by comparison with medium alone using Student’s t test.
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macrophages in response to Mip. Human monocytes/macrophages (5 × 10
5 cells/0.5 ml per well) were differentiated in a 6-day culture in the
presence of 2 ng/ml M-CSF. Recombinant Mip at 1 μg/ml was exposed for 30 min to lipoprotein classes or triglyceride emulsion before addition
to macrophages. After 4 h stimulation, supernatants were collected and their content in TNF-a were analyzed by ELISA. Each value represents
the mean ± SD of triplicates from two experiments. The results are expressed as percent of TNF-a release in the absence of serum. ***: p <
0.0001; **: p < 0.005, *: p < 0.05 determined by comparison with medium alone using Student’s t test.
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Page 5 of 14Figure 4 Effect of human plasma apoA-I, apoB, recombinant apoE2, apoE3, and LBP on TNF-a and IL-8 productions by primary
human differentiated macrophages in response to Mip. Human monocytes/macrophages (5 × 10
5 cells/0.5 ml per well) were differentiated
in a 6-day culture in the presence of 2 ng/ml M-CSF. Recombinant Mip at 1 μg/ml was exposed for 30 min to apolipoproteins or LBP before
addition to macrophages. After 4 h stimulation, supernatants were collected and their content in TNF-a and IL-8 were analyzed by ELISA. Each
value represents the mean ± SD of triplicates from two experiments. The results are expressed as percent of TNF-a or IL-8 release in the absence
of serum. ***: p < 0.0001; **: p < 0.005, *: p < 0.05 determined by comparison with medium alone using Student’s t test.
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parison between the absence and presence of human
serum because, in contrast to Mip, no or only low pro-
duction of cytokines was obtained in the complete
absence of serum. However, as already mentionned, FBS
does not contain VLDL [10,11] and contains lower con-
centrations of LDL than human serum [10], so the com-
parison of cytokine production in the presence of FBS
and in the presence of human serum allows evaluation of
the possible inhibitory effect of LDL and VLDL. Data are
reported as percent of the cytokine concentration found
in the presence of FBS with 100% corresponding to a
median TNF-a concentration of 0.28 ng/ml (IQR 0.23 -
0.73) and to a median IL-8 concentration of 9.8 ng/ml
(IQR 5.0 - 14.3) for OspA-stimulated cells, to a median
TNF-a concentration of 1.5 ng/ml (IQR 0.9 - 2.0) and to
a median IL-8 concentration of 9.9 ng/ml (IQR 4.3 -
15.9) for E. coli LPS-stimulated cells, to a median TNF-a
concentration of 0.57 ng/ml (IQR 0.13 - 1.19) and to a
median IL-8 concentration of 8.4 ng/ml (IQR 6.5 - 11.0)
for Pam2CSK4-stimulated cells, and to a median TNF-a
concentration of 1.09 ng/ml (IQR 0.71 - 1.14) and to a
median IL-8 concentration of 18 ng/ml (IQR 14 - 21) for
Pam3CSK4-stimulated cells. Compared to cytokine
release observed in the presence of 10% FBS, the produc-
tion of TNF-a and IL-8 induced by OspA, Pam2CSK4,o r
Pam3CSK4 were completely inhibited in the presence of
10% human serum but not the production induced by E.
coli LPS which were only significantly inhibited (to 44 ±
27% for TNF-a and 60 ± 10% for IL-8, p < 0.005 in both
cases)(Figure 5).
Human serum prevented proinflammatory activity of
OspA, E. coli LPS, Pam2CSK4, and Pam3CSK4 in primary
human differentiated macrophages
To extend our observations, the effect of 10% human
serum was also compared to 10% FBS in primary
human differentiated macrophages. In contrast to PMA-
differentiated THP-1 cells, the production of TNF-a
induced by OspA, Pam2CSK4,o rP a m 3CSK4 was not
completely inhibited in the presence of 10% human
serum. However significant inhibitions were still
observed (to 38 ± 11% for OspA, 15 ± 12% for
Pam2CSK4, and 41 ± 21% for Pam3CSK4, p <0 . 0 0 0 1t o
<0 . 0 0 5 )a sw e l la sf o rE. coli LPS-stimulated cells (40 ±
8%, p < 0.0001)(Figure 6A). Overall, these results sug-
gest a role for LDL and VLDL in the inhibition of cyto-
kine production observed in the presence of human
serum.
Human apoB prevented proinflammatory activity of OspA
and E. coli LPS
T of u r t h e re x a m i n et h ep o s s i b l er o l eo fL D La n dV L D L
in inhibition of proinflammatory activity of these
bacterial compounds, the ability of purified apoB, the
main structural component of LDL and VLDL, to alter
the proinflammatory activity of OspA and E. coli LPS
was next investigated. At a concentration of 10 μg/ml,
apoB was found to markedly inhibit the TNF-a and IL-
8 production induced by 1 μg/ml OspA or E. coli LPS
(to 3 ± 2% and 8 ± 6%, respectively for TNF-a produc-
tion, p < 0.0001 in both cases and to 26 ± 23% for IL-8
production, p < 0.005, in both cases)(Figure 6B and 6C).
This inhibitory effect of apoB was concentration-depen-
dent (data not shown). These data demonstrated a gen-
eral ability of purified apoB to inhibit proinflammatory
activity of bacterial components.
Low sequence homologies were found between apoA-I,
apoE, and C- terminal sequence of apoB
Because apoA-I, apoE, and apoB were shown to inhibit
TNF-a release in Mip-stimulated cells (Figure 4A),
homologies among the three apolipoprotein sequences
were studied to identify possible residues in the apolipo-
proteins that account for the neutralization of Mip. The
CLUSTALW multiple sequence alignment program was
used and similarities were found between apoA-I, apoE,
and C- terminal part of apoB. However, sequence
homologies were low since only 7 (2%) invariant resi-
dues, 54 (15%) conserved substitutions, and 28 (8%)
semiconserved substitutions were found in 362 residues
overlap (Figure 7). With pairwise alignments, the best
score (114) was obtained between apoA-I and apoE
sequences which resulted in 20.7% identity in 164 resi-
dues overlap. When pairwise alignments were performed
with apoB, lower scores were obtained: 51 with apoE
(20.9% identity in 43 residues overlap) and 46 with
apoA-I (20.8% identity in 72 residues overlap). These
results suggest that the interactions between apolipopro-
teins and Mip do not involve particular residues but
might rather involve specific domains as reported by
S e g r e s te ta l .[ 1 8 ] .T h u s ,t h eh y d r o p h o b i cs u r f a c e so f
apolipoproteins might interact with acyl chains of the
lipid part of Mip, rendering it biologically inactive and
significantly less stimulatory to macrophages because
the lipid part of Mip is responsible of its proinflamma-
tory activity [2].
Serum lipids inhibited the production of IL-8 induced by
Mip and OspA in HEK-293 cells expressing human TLR1/2
To gain further insight into the mechanism involved in
serum factor-driven attenuation of bacterial lipoprotein
proinflammatory activity and more precisely examine
the ability of serum lipids and lipoproteins to render
bacterial lipoproteins invisible to signaling receptors, the
effect of 10% human serum, 200 μg/ml HDL, LDL, or
VLDL, 0.1% triglyceride emulsion, and 10 μg/ml apoB
was tested in HEK-293 cell lines expressing human
Bas et al. BMC Immunology 2010, 11:46
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involved in the recognition of Mip [2]. HEK-293 cells
stably transfected with either the empty plasmid (293-
Null) or human TLR1/2 genes were stimulated with 1
μg/ml Mip or OspA. The IL-8 production obtained in
Mip-stimulated HEK-293 cells expressing human TLR1/
2 was markedly inhibited by the presence of serum
lipids (to 22 ± 28%, 10 ± 10%, 10 ± 10%, 27 ± 34%, 0%,
and 12 ± 8% (p < 0.005 and < 0.0001) in the presence of
10% human serum, 200 μg/ml HDL, LDL, or VLDL,
0.1% triglyceride emulsion, or 10 μg/ml apoB, respec-
tively. Similar results were obtained in OspA-stimulated
HEK-293 cells expressing human TLR1/2 (Figure 8) sug-
gesting that these factors interfered with the binding of
Mip and OspA to TLR1/2.
Discussion
Different bacteria or bacterial components are known to
interact with serum lipoproteins or apolipoproteins. The
best characterized interactions are those between E. coli
LPS and HDL [19,20] but also LDL, VLDL, and chylo-
m i c r o n s[ 2 1 , 2 2 ]a sw e l la sp u r i f i e dh u m a na p o A - I
[22-24], apoB [23], and apoE [25,26]. Lipoteichoic acid
has also been shown to interact with several plasma
lipoproteins [9,27] as well as Staphylococcus aureus a-
toxin [28], Porphyromonas gingivalis [29], Vibrio vulnifi-
cus cytolysin [30], and Streptococcus pyogenes collagen-
like protein Scl1 [31]. Very few studies have described
interactions between bacterial lipopeptides or lipopro-
tein and serum components with one report about the
binding of lipopeptides from Mycoplasma arthritidis to
Figure 5 Effect of 10% FBS and human serum on TNF-a and IL-8 production by PMA-differentiated THP-1 cells in response to OspA,
E. coli LPS, Pam2CSK4, or Pam3CSK4. Cells (2.5 × 10
5 cells/1 ml per well) were cultured with 10 nM PMA for 48 h and then stimulated by
recombinant OspA or purified E. coli LPS, both at 1 μg/ml, or 0.01 μg/ml Pam2CSK4 or Pam3CSK4 in the presence of 10% heat-inactivated FBS or
human serum. After 4 h stimulation, supernatants were collected and their content in TNF-a and IL-8 were analyzed by ELISA. Each value
represents the mean ± SD of triplicates from four experiments. **: p < 0.005, ***: p < 0.0001 determined by comparison with 10% FBS using
Student’s t test.
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pH6-Ag, a lipoprotein of Yersinia pestis, with apoB [33].
The present study adds new lipoproteins to the list of
bacterial components known to bind serum lipoproteins
or apolipoproteins. Indeed, human serum was found to
markedly inhibit Mip proinflammatory activity. When
tested independently, total lipoproteins, HDL, LDL,
VLDL or a triglyceride emulsion all had an inhibitory
effect, LDL and VLDL being the most potent. When
several apolipoproteins were tested without their physio-
logical lipid complement such as purified apoA-I, apoB,
apoE2, and apoE3, all showed an inhibitory effect, apoB
Figure 6 Effect of 10% FBS and human serum on TNF-a productions by primary human differentiated macrophages in response to
OspA, E. coli LPS, Pam2CSK4, and Pam3CSK4 and effect of 10 μg/ml apoB on TNF-a and IL-8 production induced by OspA and E. coli
LPS. Human monocytes/macrophages (5 × 10
5 cells/0.5 ml per well) were differentiated in a 6-day culture in the presence of 2 ng/ml M-CSF
and then stimulated by recombinant OspA or purified E. coli LPS, both at 1 μg/ml, or 0.01 μg/ml Pam2CSK4 or Pam3CSK4 in the presence of 10%
heat-inactivated FBS or human serum (A) or in the presence of 10 μg/ml human plasma apoB (B and C). After 4 h stimulation, supernatants
were collected and their content in TNF-a and IL-8 were analyzed by ELISA. The results are expressed as percent of TNF-a or IL-8 release in
presence of 10% FBS. Each value represents the mean ± SD of triplicates from two experiments. **: p < 0.005, ***: p < 0.0001 determined by
comparison with 10% FBS using Student’s t test.
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cannot be attributed to sequence similarity between the
different apolipoproteins but rather to similarity in their
lipid-associating domains. Indeed, apoA-I and E are
characterized by an abundance of amphipathic a-helices
[34] responsible for their lipid binding character [35]
and it has been shown that the a2a n da3d o m a i n si n
apoB-100, corresponding to the two major apoB-100
lipid-associating domains, are homologous to certain
amphipatic helix-containing regions of apoA-I and apoE
[18]. All these amphipatic domains might interact with
the acyl chains of the lipid-modified cysteine at the
amino-terminus of Mip.
The possible involvement of LBP in Mip inactivation
was also investigated but was found to be poor compared
to apoB ability. This result agrees with the absence of
LBP effect on cytokine production induced by B. burg-
dorferi OspA, another lipoprotein [36,37]. In addition,
human serum was able to decrease TNF-a production
induced by synthetic triacylated and diacylated lipopep-
tides, OspA, and E. coli LPS and apoB was able to inacti-
vate OspA and E. coli LPS. Results obtained with HEK-
293 cell lines expressing human TLR1/2 showed that
serum factors attenuated proinflammatory activity of
both Mip and OspA through their binding to TLR1/2.
These results allow us to hypothesize that an attenuation
of bacterial lipoprotein proinflammatory activity may
occur in blood and in all body compartments where
serum lipoproteins are present. This observation may
have an important impact because bacterial lipoproteins
are produced by the complete spectrum of bacterial
pathogens [38] and have been implicated in inflammatory
processes and in pathogenesis of several important bac-
terial infections, including Leptospira interrogans [39],
Mycobacterium tuberculosis [40], Treponema pallidum
[41], Listeria monocytogenes [42], and Borrelia burgdor-
feri [41]. Lipoproteins can be spontaneously released
from membranes when cells are lysed [43,44] and treat-
ment of bacteria with antibiotics has been shown to sig-
nificantly enhance bacterial lipoprotein release [45].
Thus, bacterium-associated lipoproteins have been found
in culture supernatants [45,46], infected tissues [47], or
the bloodstream in gram-negative sepsis [47]. For whole
bacteria, the serum lipoprotein deposition on the bacter-
ial surface could prevent recognition of the pathogen by
the host defense and be detrimental by impairing the
antibacterial response but this mechanism might also be
of benefit by preventing ongoing excessive inflammation.
However, if this mechanism could play a role in whole
blood, in extravascular compartments or at mucosal sur-
faces, where serum lipoprotein concentrations are lower,
bacterial lipoproteins can have proinflammatory effects
similar to those described in vitro in the absence of
serum. For Chlamydiae that are not primarily blood-
stream infectious agents but rather bacteria infecting
lung, urogenital system or eyes, i.e. serum-free compart-
ments, the recognition and responses would be much
more sensitive than in the circulation. However, plasma
components can leak into the sites of infection and
antagonize the stimulatory effect induced by bacteria. For
example, cervico-vaginal fluid [48,49] and tears [50] have
been shown to contain apoA-I. As previously described
Figure 7 Sequence alignment of human apoA-I (accession number P02647, 267 residues), apo B (P04114, 4563 residues), and apoE
(P02649, 317 residues) as performed by the CLUSTAL multiple alignment program. Asterisks indicate identities and colons (conserved
substitutions) and periods (semiconserved substitutions) indicate similarities in the lines below the sequences.
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host cell activation and involving bacterial lipoprotein/
lipopeptide interaction with CD14 and TLR2/1/6, and
another leading to deactivation and involving bacterial
lipoprotein/lipopeptide sequestration by serum lipopro-
teins. Depending on body compartments, bacterial lipo-
proteins should be viewed as a double-edged sword in
host-pathogen interactions: they can serve both as signal
recognized by the host to activate its defenses and limit
infection and as agents causing excessive host damage by
the pathogen in some situations.
Concerning the mechanism involved in bacterial lipo-
protein inactivation by apolipoproteins, it is possible to
hypothesize that this is effected by the constitution of
micelles between the hydrophobic structure of apolipo-
proteins and the hydrophobic part of bacterial lipopro-
teins. For the inactivation by triglycerides, it is probably
mediated by a lipid-lipid interaction with the fatty acyl
chains of the lipid portion of bacterial lipoproteins. The
lipid component of bacterial lipoprotein, known to be
the moiety causing monocyte/macrophage activation [2],
would be sheltered or sequestered and unable to bind to
Figure 8 Effect of human serum, LDL, triglyceride emulsion, and apoB on the production of IL-8 by HEK-293 cell line expressing
human TLR1/2, upon Mip and OspA activation. Null and hTLR1/2 cells were stimulated with 1 μg/ml Mip or OspA for 24 h in the presence
or absence of serum lipids. Culture supernatants were collected and IL-8 content was analyzed. Background values (unstimulated) were
subtracted. Each value represents the mean ± SD of triplicates from two experiments. **: p < 0.005, ***: p < 0.0001 determined by comparison
with bacterial component alone using Student’s t test.
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Page 11 of 14cell receptors. It has been shown that apoB-containing
lipoproteins prevented binding of pH6-Ag to THP-I
monocyte-derived macrophages [33]. The present study
has shown that serum lipoproteins inhibited TLR1/2-
mediated proinflammatory response to two bacterial
lipoproteins, Mip and OspA.
Conclusions
In conclusion, this study shows that a close relationship
exists in vitro between serum and bacterial lipoproteins
that is able to influence proinflammatory activity of bac-
terial components.
Methods
Reagents
Recombinant Mip lipoprotein was purified as previously
described [52] and subsequently treated by polymyxin
B-agarose (Sigma-Aldrich, Buchs, Switzerland) [2].
Recombinant Borrelia burgdorferi outer surface protein
A( O s p A )w a sp u r c h a s e df r o mB i o d e s i g nI n t e r n a t i o n a l
(Milan Analytica, La Roche, Switzerland). Racemic
Pam3CSK4 (Pam3-Cys-Ser-Lys4-OH) and Pam2CSK4
(Pam2-Cys-Ser-Lys4-OH) used as synthetic triacylated
and diacylated control lipopeptides, respectively, were
obtained from EMC Microcollections (Tuebingen, Ger-
many). LPS from Escherichia coli serotype O55:B5 was
purchased from Sigma-Aldrich and repurified [2].
Human serum and FBS was from Invitrogen (Basel,
Switzerland). Delipidated FBS was purchased from
Sigma-Aldrich. Long- and medium-chain triglyceride
emulsion (Lipofundin; 20%, w/v) was from B. Braun
(Melsungen, Germany). Human plasma apoA-I and B
were from Calbiochem (Merck Biosciences, VWR Inter-
national, Dietikon, Switzerland). Recombinant apoE2
and E3 were from Invitrogen. Recombinant LBP was
obtained from Biometec (Greifswald, Germany).
Preparation of lipoproteins
Total serum lipoproteins were isolated from human
serum by salt gradient ultracentrifugation at d < 1.21
gm/cm
2. HDL, LDL, and VLDL were isolated by sequen-
tial density ultracentrifugation as described previously
[53,54] and dialyzed for 48 h against PBS or RPMI. Pro-
tein concentrations were determined by using a micro-
bicinchoninic acid protein assay kit (Pierce, Perbio
Science, Switzerland) using BSA as a standard.
THP-1 cell culture
The method of THP-1 cell culture was previously
described [2]. Briefly, THP-1 cells were grown in RPMI
1640 medium. For monocytic differentiation, they were
seeded in 24-well flat-bottom tissue culture plates at a
density of 2.5 × 10
5 cells/1 ml per well and allowed to
adhere and differentiate 48 h at 37°C in the presence of
10 nM PMA (Sigma-Aldrich). After repeated washing
with RPMI 1640, PMA-differentiated THP-1 cells were
stimulated at 37°C with indicated stimuli. Cell-free
supernatants were harvested after 4 h (or indicated time
periods) of incubation and kept at -70°C until cytokine
measurements.
Human differentiated macrophage culture
The study protocol was approved by Institutional Ethics
Committee (Geneva University Hospital, Switzerland).
Informed consent was obtained from all subjects. The
method of monocyte/macrophage preparation was pre-
viously described [2]. Briefly, peripheral blood mononuc-
lear cells from healthy blood donors were isolated by
density gradient centrifugation with Ficoll-Hypaque
(Amersham Biosciences, GE Healthcare Europe GmbH,
Otelfingen, Switzerland). Monocytes/macrophages were
separated by aggregation, gradient of FBS, and rosetting.
Macrophages were generated by differentiation of puri-
fied monocytes/macrophages using a 6-day culture in
the presence of 2 ng/ml macrophage-colony-stimulating
factor (M-CSF) (R&D Systems, Abingdon, UK). Mono-
cytes/macrophages were seeded into 24-well flat-bottom
tissue culture plates at a concentration of 5 × 10
5 cells/
0.5 ml per well in RPMI 1640 containing 2 mM Gluta-
MAX I, supplemented with 100 U/ml penicillin, 0.1 mg/
ml streptomycin, and heat inactivated (30 min at 56°C)
endotoxin-free 10% (v/v) human serum (Invitrogen).
The medium was refreshed regularly. After 6-day differ-
entiation, cultures were washed five times with medium
without serum. Recombinant Mip was exposed for 30
min to human serum, isolated lipoproteins, or triglycer-
ide emulsion before addition to macrophages. After 4 h
stimulation at 37°C with indicated stimuli, cultures were
centrifuged at 400 × g for 10 min at 4°C and cell-free
supernatants were collected and stored at -70°C until
TNF-a measurements.
Cytokine measurements
Extracellular release of TNF-a and IL-8 was determined
by a sandwich ELISA technique using the DuoSet
ELISA Development Systems (R&D), according to the
manufacturer’s instructions. The ELISA detection limits
were 2 pg/ml.
Sequence alignments
The sequences of apoA-I, apoB, and apoE were found in
the Swiss-Prot/TrEMBL database. To study homologies
among the three apo sequences, the CLUSTALW multi-
ple sequence alignment program was used. To study
homologies between two sequences, the SIM binary
sequence alignment program [55] (available at http://
www.expasy.org/tools/sim-prot.html) was used with Blo-
sum62 as a comparison matrix.
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Page 12 of 14Response of TLR1/2 cell lines
Nonphagocytic HEK-293 cells stably transfected with
either the empty plasmid (293-Null) or human TLR1/2
genes were purchased from InvivoGen (LabForce, Nun-
ningen, Switzerland) and maintained in Dulbecco’s
Modified Eagle Medium (Invitrogen) supplemented with
4.5 g/l glucose, 10% FBS, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, and 10 μg/ml blasticidin S (InvivoGen).
For stimulation experiments, stable transfected cells
were seeded into individual wells of a 48-well flat-bot-
tom tissue culture plate at a concentration of 3 × 10
5
cells/0.3 ml per well of complete medium and allowed
to adhere overnight. The following day, fresh medium
was added and the cells were stimulated with indicated
stimuli for 24 h. Culture supernatants were collected
and IL-8 content was analyzed.
Statistical analysis
Statistical analyses were performed using the Student’s
t test with the SPSS statistical software (for Macintosh,
v.10). Differences were considered significant at p <
0.05.
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